E*TRADE View E*TRADE Products & Accounts Help

*
Accounts
*
Investing
*
Tools &
Research

Quote:
Logoff

*
Markets
* |
*
News
*
Company Profile
*
Charts
* |
*
Stock Screener
* |
*
Heat Maps
* |
*
Performance Tables
* |
*
Technical Analysis


14 Dec, 2009 15:41 UK
Symbol Lookup
FTSE 1005,309.2847.71
Close

* Snapshot
* Charts
* Prices
* Trades
* News
* Broker Views
* Director Dealings
* Star Ratings
* Fundamentals
* Profile

XCounter AB (XCT) Buy Now Sell Now
Annual Report

Sector:
Health Care Equipment & Services

Share Price
5.50p

Change Today
0.000p

Market Cap
2.40m

* Overview
* Regulatory News
* ShareCast

Subsidiary signs major development agreement

RNS Number : 0851E
XCounter AB
14 December 2009




PRESS RELEASE




XCounter's subsidiary signs major development agreement to supply innovative monitoring detectors to the energy industry


Stockholm, 14 December 2009: XCounter AB (AIM: XCT) ('XCounter' or 'the Company'), a leader in the development of photon counting detector and tomosynthesis-based 3D imaging technology, today announces that its subsidiary, Oy AJAT Ltd ("AJAT"), has signed a seven year exclusive agreement to supply its X-ray detector technology to a Norwegian company specializing in industrial technology development within the energy industry (the "Commercial Partner").

Pursuant to the agreement, AJAT will receive orders with minimum purchase values increasing each year up to and including 2015 and worth in aggregate 8.2m. The Commercial Partner has the option to extend the contract by two years on three occasions up to a total of six years.


AJAT and the Commercial Partner will work together on the development of these new detector products and other related technologies with broader applications to the energy industry.


AJAT and the Commercial Partner have been working together and have already completed the first stage of the customized technology for detection devices.


This agreement is a major step in XCounter's strategy to focus on specialty digital detector technologies for medical, dental and industrial applications.


XCounter owns 49.8% of AJAT and has a call option for the remaining 50.2%.

Mikael Strindlund, CEO of XCounter commented:


"Today's announcement is a further validation of our focus on developing and marketing specialty X-ray detector technologies for different application fields. We are delighted to have entered into this long term agreement and are looking forward to further developing our relationship with this key customer.

XCounter AB (publ) (AIM:XCT), a technology leader in the development of tomosynthesis-based 3D medical imaging, announced positive initial results from the first clinical evaluation of its innovative breast screening device XC Mammo - 3T. The device is the world's first dedicated 3D digital mammography system for the detection of breast cancer, the most common form of cancer found in women.

Conducted in April 2009, the independent study by the mammography departments of Danderyd University Hospital and the Karolinska University Hospital evaluated the clinical benefits of using the new tomosynthesis-based 3D imaging compared with traditional 2D digital mammography. The study was based on 150 patients, each selected on the basis they required additional scanning due to suspicious lesions found during initial scans.

The results indicate that the XC Mammo - 3T, offers the same sensitivity from one tomosynthesis image compared to two images from 2D digital mammography, despite the fact that the patient selection was based on the 2D images by expert radiologists that currently have limited training in reading tomosynthesis images.

Dr. Gunilla Svane, associate professor of radiology at Karolinska University Hospital highlighted the XC Mammo - 3T prototype demonstrated a number of benefits over traditional 2D imaging: "One of the major limitations of 2D images is that it is difficult to discern individual features in dense breasts which mean that we may get false negative findings. The tomosynthesis technique makes each structure stand out in a way which makes it easier to detect tumours. In the 3D images the extent of the feature is also more obvious, particularly for spiculated masses. Micro-calcifications are as clearly visible in the XC Mammo -3T images as they are in 2D. In addition, it is easier to see the extension and the growth pattern of the calcifications in the three dimensional representation than in the 2D images where one is limited to two views."

Dr. Edward Azavedo, associate professor of radiology at Karolinska University Hospital continued: "The ability of the XC Mammo -3T images to detect malignancy is just as high as the 2D images. However, the possibility to single out masked lesions in dense breasts also means that we will probably be able to detect more abnormalities and cancers in this category without additional examinations, such as ultrasound. The patient response has been very positive and the patients have stated that the 3D examination was much more comfortable than the regular 2D exam where amongst other things the compression force on the breast in general is higher".

Mikael Strindlund, CEO of XCounter said:
"The positive results of our first prototype installation in a clinical environment is a major achievement for XCounter. I am particularly encouraged to hear that, unlike other imaging systems, XC Mammo - 3T can confidently detect micro-calcifications, helping to identify abnormalities earlier in their development."

The findings from the independent clinical evaluation will be developed into a comprehensive clinical report during 2009.

XCounter AB (publ) (AIM: XCT), a technology leader in the development and
commercialisation of 3D medical imaging, has announced a commercial partnership
with the global leader in brachytherapy, Nucletron B.V.


In this first step of the cooperation between Nucletron and XCounter, the latter will evaluate
the properties of a novel imaging system for brachytherapy treatments. This evaluation is a
pre-study prior to moving to a full agreement on the development of a dedicated imaging
system for brachytherapy, especially designed for Nucletron.


The incidence of most cancer types is growing. Approximately 50% of all men and 30% of
all women in the USA will develop some kind of cancer at some point in their lives (NIH,
2002). This means that the need for effective methods for cancer treatment, such as
brachytherapy, is growing rapidly.


High image quality and low dose imaging are vital components in precision cancer
treatment. We find XCounters imaging principles very attractive and are looking forward to
the results of this pre-study, says Dick van Waes, Business Director Brachytherapy and
Imaging of Nucletron.


It is with great pleasure that we can announce XCounters commercial partnership with
Nucletron. Nucletron has chosen to cooperate with XCounter as a result of our unique
imaging concepts, as well as our ability to handle development on behalf our customers. In
line with our business concept, which is to invent and develop innovative patient and disease
specific imaging systems and concepts for leading medical companies, the agreement is a
further recognition of the capabilities of our company as we continue partnering discussions
for the XC Mammo -3T, says Tom Francke, CEO at XCounter. We are looking forward to a
fruitful cooperation with Nucletron.


Brachytherapy is a high precision, minimally invasive radiation therapy, favourably used for
cancer treatment in parts of the body which have sensitive adjacent organs. Examples of such
treatment areas are gynaecological body sites, breast, bladder, brain, head and neck, lung,
esophagus and prostate

XCounter's subsidiary signs major development agreement to supply innovative monitoring detectors to the energy industry


Stockholm, 14 December 2009: XCounter AB (AIM: XCT) ('XCounter' or 'the Company'), a leader in the development of photon counting detector and tomosynthesis-based 3D imaging technology, today announces that its subsidiary, Oy AJAT Ltd ("AJAT"), has signed a seven year exclusive agreement to supply its X-ray detector technology to a Norwegian company specializing in industrial technology development within the energy industry (the "Commercial Partner").

Pursuant to the agreement, AJAT will receive orders with minimum purchase values increasing each year up to and including 2015 and worth in aggregate 8.2m. The Commercial Partner has the option to extend the contract by two years on three occasions up to a total of six years.


AJAT and the Commercial Partner will work together on the development of these new detector products and other related technologies with broader applications to the energy industry.


AJAT and the Commercial Partner have been working together and have already completed the first stage of the customized technology for detection devices.


This agreement is a major step in XCounter's strategy to focus on specialty digital detector technologies for medical, dental and industrial applications.


XCounter owns 49.8% of AJAT and has a call option for the remaining 50.2%.

Mikael Strindlund, CEO of XCounter commented:


"Today's announcement is a further validation of our focus on developing and marketing specialty X-ray detector technologies for different application fields. We are delighted to have entered into this long term agreement and are looking forward to further developing our relationship with this key customer."

Picturing Change
As imaging technology advances, the ways in which healthcare professionals do their job also changes. But what are the next big developments to come out of R&D and how will they impact on the role of the radiologist? GlobalData looks at the work being undertaken by manufacturers and academia and how it is changing the face of diagnostic imaging the world over.

Date: 08 Oct 2009
Email Article

Print

Link to us
Link To Us

Precision and diagnostic accuracy will be the key factors deciding acceptance and market penetration of about 176 diagnostic imaging devices currently at various stages of development. This article uses the Medical eTrack Products Pipeline Database to identify those products and technologies that are expected to revolutionalise the way healthcare professionals diagnose and treat life-threatening conditions.

Mammography
There are about 24 mammography products under different stages of clinical investigations, but the following devices, when launched, are the ones expected to make diagnosis of breast cancer more accurate with minimum instances of false positives and false negatives.

Digital breast tomosynthesis (DBT)
Being developed independently by GE Healthcare, Siemens Healthcare, the US-based Hologic and the UK-based Dexela Limited, the DBT-based mammography system acquires, processes and visualises data from 3D X-ray images making it easier than ever before to detect tumors even in dense breast tissues. DBT reconstructs a 3D composite image from a series of 11, low-dose 2D images, enabling physicians to view the interior of the breast without hindrance from surrounding superimposed breast tissues.

This results in identification of tumors that are easy to miss with the conventional 2D approach. Currently under clinical investigations, the system, once approved, is expected to redefine the breast cancer diagnosis and treatment landscape.

Computed tomography laser mammography (CTLM) system
Currently under development, the CTLM system from Imaging Diagnostic Systems Inc. is a non-invasive device that uses lasers to image the breast. Unlike an X-ray mammography system, CTLM images blood haemoglobin and the process of new vessel formation, a physiological development often associated with breast cancer.
"The CTLM system is a non-invasive device that uses lasers to image the breast."

The system images through breast implants and dense breast tissue easily, which traditional mammography finds difficult to penetrate. With its ability to visualise tumors in the evolving process, CTLM is expected to provide early diagnosis and hence early treatment, leading to breast-sparing surgery and less trauma to the patient.

Imaging Diagnostic Systems, Inc. is currently collecting data from clinical sites for the future filing of a US Food and Drug Administration (FDA) Premarket Approval (PMA) for its CTLM system.

Amulet full field digital mammography (FFDM) system
Fujifilm Corporations Amulet is the worlds first digital mammography system equipped with the direct conversion flat panel detector (FPD) technology. The system provides a small pixel size of 50m yet produces both high-resolution and low-noise images, making image quality its key feature.

The product is also said to offer the opportunity for reduced dose and enhanced workflow efficiency. Already launched in Japan, it is awaiting FDA approval nod for sale in the US, where it is expected to be marketed under the Aspire brand of breast imaging products.

The US launch of this system will make Fujifilm the first womens healthcare company offering both computed radiography (CR) and digital radiography (DR) FFDM solutions.

Computer tomography (CT)
Dominion Vi 3D medical imaging scanner
The Dominion Vi 3D medical imaging scanner being developed by the Californian-based Imaging3 Inc. employs high-resolution photo-fluoroscopy to produce 3D diagnostic images on a real-time basis. Since these images are produced real time, they have the potential to be used for any current or new medical procedure that requires multiple frames of reference to perform the procedure in the human body.

In April 2008 Imaging3 received the US FDA approval to begin distributing the product for evaluating its effectiveness in the clinical setting. Touted by the company as a safer and cost-effective alternative to CT scanning, the device stands to benefit many medical specialities, including trauma, cardiology, pain management, paediatrics, orthopaedics, sports medicine, vascular, and neuro-vascular.

Magnetic resonance imaging (MRI)
There are about 20 MRI systems at various stages of development that will transform the MRI technology landscape. Several, however, are expected to revolutionise MRI-based diagnosis.

11.7T MRI system
Being developed by the French Atomic Energy Commission (CEA) in collaboration with Siemens Healthcare and Alstom Magnets and Superconductors, within the framework of the French-German consortium Iseult/INUMAC (Imaging of Neuro disease Using high field MAgnetic resonance and Contrastophores), the 11.7T MRI system is expected to address clinical applications of ultra high-field (UHF) MRI.

7T MRI system
The 7T MRI system, while offering the potential for microscopic spatial resolution, also enables the observation and analysis of tissue metabolism and function.

A Siemens Healthcare development, 7T MRI systems are investigational devices and are not available for clinical use. Currently, they are being used only for clinical research and not for clinical diagnosis.

It is expected that the 7T MRI system will make it possible to study neuronal function at the sub-millimeter scale. Potential clinical applications include neurodegenerative diseases like Alzheimers.

Renaissance system 1000
The product of a partnership between US-based ViewRay, Inc. and Siemens Healthcare, the Renaissance System 1000 combines MRI and gamma ray radiotherapy technologies to provide real-time beam-on imaging and targeting of the tumor.

MRI coil devices
Being developed by the US-based Tursiop Technologies LLC, the nanomaterial-based MRI coil devices are expected to produce better image quality and faster scan times, thus boosting the functional capabilities of any installed MRI system.

X-ray
XCT -3T
XCounter AB from Sweden is behind the XCT -3T, a 3D digital tomosynthesis technology that captures 3D digital X-ray images, resulting in high-resolution imaging at low levels of radiation. The Swedish company is pursuing the development of four systems.

They are the XC Mammo -3T, a prototype system for 3D digital breast tomosynthesis screening; the XC MP-3T, a 3D general-body imaging system; XC Cardio -3T, a cardiac-imaging system designed for 3D functional imaging of the heart; the Cardio -4T, a cardiac-imaging system designed for repetitive 3D imaging of the heart.

Magnetic particle imaging (MPI)
Magnetic particle imaging (MPI) technology uses magnetic properties of iron-oxide nanoparticles injected into the bloodstream to generate real-time images of arterial blood flow and volumetric heart motion. Because the human body doesnt naturally contain nanoparticles, the MPI technology, by combining high spatial resolution with short image acquisition times, captures dynamic concentration changes as the nanoparticles flow along with the bloodstream.

Currently in pre-clinical stages, the first 3D imaging results with this system were announced by Philips Healthcare, the company developing the technology, in March 2009. The company was the first in the world to demonstrate the use of MPI in producing real-time in-vivo images, which capture cardiovascular activities, accurately and in real-time.

It noted that by augmenting important functional details to the anatomical data obtained from conventional modalities such as CT and MR, the MPI technology has the potential to help in the diagnosis and treatment planning of major cardiovascular diseases such as atherosclerosis and congenital heart defects.
"Scientists have invented a magnetic molecule, Fe8, that is a highly effective contrast solution with potential to be used in medical imaging."

Academia in action
MRI/PET scanner
Researchers at the University of California, Davis Campus in the US have successfully combined the technological capabilities of positron emission tomography (PET) and magnetic resonance imaging (MRI) to build a single scanner the MRI/PET scanner. While combination scanners that combine computer-assisted tomography (CAT) and PET scans are already available in the market, the fact that CAT scans provide less structural details (especially of soft tissues) than MRI scans, makes the MRI/PET scanner a breakthrough technology, which is under development. As standalone units, MRI scans provide high-quality structural images but hardly any functional detail; whereas PET scans show body processes but no structural detail.

Fe8 Scientists at the National Institute of Standards and Technology in collaboration with researchers at the Florida State University and the University of Colorado at Boulder in the US have invented a magnetic molecule, named Fe8, that is harmless, predictable and thus a highly effective contrast solution with potential to be used in medical imaging.

As should be clear from our product and technology profiles, precision and diagnostic accuracy remain the key innovation areas of interest, and its not just the imaging giants but also the small and medium manufacturers that are expected to bring dynamism to the diagnostic imaging technology landscape.

imaging on the way

There are 176 diagnostic imaging devices currently at various stages of development.

About 24 mammography products are under different stages of clinical investigations at present.

It is estimated that some 20 MRI systems are at various stages of development.

In 2008 the global diagnostic imaging market was worth $16bn.

State of the global diagnostic imaging market

In 2008 GE Healthcare, Philips Healthcare and Siemens Healthcare together accounted for more than 70% of the global diagnostic imaging market, which was valued at $16 billion. With a combined pipeline portfolio of about 20 products at different stages of clinical investigations, GE, Philips and Siemens are well positioned to further penetrate a market that is forecast to grow at 6% annually for the next seven years to reach $24.2 billion by 2015.

Source: Medical eTrac

http://docs.google.com/viewer?a=v&q=cache:TARtNRQtTtUJ:www.xcounter.se/uploads/xcounter/pdf/090325XCT%2520Acquisition%2520of%2520AJAT%2520-%2520FINALCLEAN%2520_2_%2520homepage.pdf+XCOUNTER+AB/admission+document&hl=en&gl=uk&pid=bl&srcid=ADGEESjjBLF3xPb3SoNGQzOWPtUKjytW9cruPShm7xOuyT8MK9kHfUV5nGKMNtQM7DgpvLt6a2yOHVvM3Fw2KIS-jhPvQnKrF867E8fKQ1vFaTWebi5vtWxMJJq-pZZw7SwFqMzQetvc&sig=AHIEtbSjl8K67nU1Z4CrYj0gWUDjKz_1KQ

http://www.mandadeals.co.uk/m-and-a-deals/international/1044157/xcounters-xray-vision.thtml
XCounters X-ray vision
By Patrizia Rossi on May 08 2009

XCounter AB, an AIM-traded Swedish developer of low-radiation 3D digital X-ray imaging technology, has acquired a 49.8 per cent stake in Oy AJAT, a Finnish manufacturer of digital solid-state X-ray detectors, for 3.4 million (3 million). XCounter is set to pay a further 1.05 million if certain performance targets are met.

The Swedish company has entered into option agreements with the company, which will give it the right to up its stake by 19 per cent in 12 to 18 months in exchange for 13 million shares in XCounter, representing some 30 per cent of the companys current issued share capital. The companys intention is to acquire 100 per cent of AJAT. However, details of how and when this will happen have not been released.

The acquisition brings AJATs solid-state detector technologies for the medical and industrial markets to XCounters product portfolio and propels the Swedish corporate into new markets, the company said.

Mikael Strindlund, CEO of XCounter, said: This is a very exciting acquisition, that creates the opportunity to build a world-class, sustainable X-ray detection business based on a leadership position in photon-counting technologies. The combination of XCounters and AJATs technologies will enable XCounter to open up new and exciting markets and allow the company to achieve its primary objective of creating value for shareholders.

3D medical x-ray company Xcounter arrives on AIM
by William Foss

Xcounter AB (XCT) hit the ground running on announcing it?s admission to AIM today.

The company raised 16 million before expenses at an IPO price of 155p/share, and on listing this morning the shares started trading at a 25% premium at 197p.

Xcounter has developed a new technology for capturing 3D X-ray images which create a considerably higher quality image combined with a lower radiation dose than tradition X-ray machines. The company intends to use the funds raised to complete the development and build the first units with the intention of targeting the mammography and general body imaging sectors of the health-care industry.

"Senses Working Overtime"

1st detector orderedXCounter AB



XCounter AB and Artemis Imaging GmbH to develop breast CT scanner



2 July 2009: XCounter AB (publ) (AIM: XCT), a technology leader in the development of photon counting detector and tomosynthesis-based 3D medical imaging, today announced it is working with Artemis Imaging GmbH, a spinoff of the University of Erlangen's Institute of Medical Physics, on the development of an innovative 3D Breast CT system. The new device may have the potential to offer more comprehensive and higher quality breast scanning facilitating earlier detection of breast cancer, the most common form of cancer found in women.



Artemis Imaging GmbH, under the leadership of Prof. Willi Kalender, has substantial expertise and a proven track record in CT physics, system and applications development. It intends to develop, validate, clinically test and commercialize a low-dose, high-resolution breast CT scanner using the XCounter digital direct conversion solid state detector technology.



The new device will offer multiple views of the breast, while XCounter's photon counting technology will increase the overall quality of imaging.



Prof. Willi Kalender, CEO of Artemis Imaging GmbH stated:
"We selected the XCounter photon counting technology because we believe it meets the requirements for a revolutionary new dedicated breast CT system which combines the highest image quality with the lowest radiation dose to the patient."



Mikael Strindlund, CEO of XCounter commented:

"Today's announcement is further validation, by world-renown experts, of our leading photon counting solid state detectors and its potential to assist in the earlier identification of one of the most common forms of cancer."


XCounter's technology includes recently acquired AJAT technologies and XCounter's photon counting technology. Artemis Imaging GmbH aims to qualify the technology as soon as it becomes available; a first detector has already been ordered for evaluation.

dtechinsight.com/ReportA409.html. It is a snapshot of the page as it appeared on 5 Dec 2009 22:09:03 GMT. The current page could have changed in the meantime. Learn more

Text-only version
These search terms are highlighted: xcounter These terms only appear in links pointing to this page: ab cancer


Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
12/16/2009




Online Report Subscribers, Click Here

Pricing and Ordering Information

U.S. Markets for Breast Cancer Detection and Diagnostic Technologies
Report #A409 - October 2009
351 Pages 103 Exhibits - 13 Company Profiles

According to the American Cancer Society (ACS), breast cancer is the most common cancer among women (excluding non-melanoma skin cancers), accounting for more than 1 in 4 cancers diagnosed in United States (U.S.) women. In 2009, approximately 192,370 women will be diagnosed with breast cancer and approximately 40,170 will die of the disease. However, due to the increased awarenesss, availability, and adoption of highly effective breast cancer screening technologies, the average 5-year relative survival rate for early stage, localized breast cancer now approaches 100%, emphasizing the importance of early breast cancer detection and diagnosis.

The U.S. breast cancer detection and diagnostic technologies market (defined in this report as including the 3 core imaging modalities of mammography, magnetic resonance imaging [MRI], and breast ultrasound, as well as minimally invasive breast biopsy and genetic testing) totaled more than $2.1 billion in the U.S. in 2008. This market is expected to grow at a healthy compound annual rate of 5.4% to more than $2.8 billion in 2013, despite the present economic uncertainty, impending healthcare reform, and cost/reimbursement issues.

As the population continues to age and the number of new breast cancer cases increases, the renewed importance on lowering healthcare costs will result in increased utilization of cost-effective, accurate, early cancer detection and prevention technologies. Next-generation imaging technologies that help lower the number of unnecessary biopsies while allowing for earlier detection with increased sensitivity and specificity over conventional mammography will be willingly adopted, and minimally invasive biopsy and genetic testing will continue to flourish. Minimally invasive biopsy systems will be increasingly preferred over open biopsy due to the ability to lessen patient disfigurement and pain. At the same time, the genetic testing products market will benefit from several factors including the ability to assist clinicians in recommending preventive care for women at high risk of contracting breast cancer, while sparing existing breast cancer patients unnecessary painful or ineffective chemotherapy by aiding in the selection of the most appropriate treatment plan.

This dynamic, new report from Medtech Insight includes analyses of products, markets, competitors, and opportunities in the U.S. breast cancer detection and diagnostic technologies market. Product areas include: analog and full-field digital mammography (FFDM) systems; computer-aided detection (CAD); computed radiography detectors; MRI systems and ultrasound systems used in breast imaging; minimally invasive biopsy; BRACAnalysis and other genetic testing (recurrence risk assays); and emerging technologies such as digital tomosynthesis, next-generation breast MRI and ultrasound, and technologies developed by several start-up companies entering the breast cancer detection and diagnostic products field.

Ordering Information

Title
Report# Publication
Date List Price

U.S. Markets for Breast Cancer Detection and Diagnostic Technologies


A409


October 2009


$4,750
Order Online:
Single User only (Please call for corporate subscription pricing) PDF Only

Print versions of Reports are available upon request for an additional fee.

Methodology
Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.



TABLE OF CONTENTS



EXECUTIVE SUMMARY

i. Common Types of Breast Cancer

ii. Symptoms

iii. Risk Factors

iv. Early Detection

v. Treatment

vi. Risk Reduction

vii. Future Directions in Breast Cancer Detection

viii. Breast Cancer Detection and Diagnostic Technologies Market



Exhibit ES-1: Cancer Cases and Deaths, by Anatomic Site, 2007, 2008, and 2009

Exhibit ES-2: 2008, 5-Year Breast Cancer Survival Rates, by Stage

Exhibit ES-3: 2008, Breast Cancer Survival Rates, 5-, 10-, and 15-Years Post-Diagnosis

Exhibit ES-4: Age-Specific Risk of Developing Invasive Breast Cancer

Exhibit ES-5: 2007, Breast Cancer Cases and Deaths, by Age

Exhibit ES-6: Selected Limitations of Mammography

Exhibit ES-7: Selected Breast Cancer Imaging Technologies

Exhibit ES-8: Breast Cancer Detection and Diagnostic Technologies, Combined Market Forecast, 2008-2013

Exhibit ES-9: 2008, Breast Cancer Detection and Diagnostic Technologies Market, Share by Segment

Exhibit ES-10: 2013, Breast Cancer Detection and Diagnostic Technologies Market, Share by Segment

Exhibit ES-11: 2008, Combined Breast Cancer Detection and Diagnostic Technologies Market, Share by Supplier



1. CLINICAL overview

1.1 Common Types of Breast Cancer

1.2 Symptoms

1.3 Risk Factors

1.3.1 Benign Breast Conditions

1.3.2 Family/Personal History

1.3.3 Genetic Risks

1.4 Early Detection

1.5 Treatment

1.5.1 Biologic Therapy, Chemotherapy, and Hormone Therapy

1.6 Risk Reduction

1.7 Future Trends in Breast Cancer Detection



Exhibit 1-1: Cancer Cases and Deaths, by Anatomic Site, 2007, 2008, and 2009

Exhibit 1-2: 2008, 5-Year Breast Cancer Survival Rates, by Stage

Exhibit 1-3: 2008, Breast Cancer Survival Rates, 5-, 10-, and 15-Years Post-Diagnosis

Exhibit 1-4: Age-Specific Risk of Developing Invasive Breast Cancer

Exhibit 1-5: 2007, Breast Cancer Cases and Deaths, by Age

Exhibit 1-6: Benign Breast Disease, by Category

Exhibit 1-7: Selected Benign Breast Diseases

Exhibit 1-8: Selected Limitations of Mammography

Exhibit 1-9: Selected Breast Cancer Imaging Technologies



2. MAMMOGRAPHY

2.1 Analog Mammography Systems

2.1.1 GE Healthcare/General Electric

2.1.2 Hologic

2.1.3 Planmed/Planmeca Group

2.1.4 Siemens Healthcare/Siemens

2.1.5 Others

2.2 Digital Mammography Systems

2.2.1 GE Healthcare/General Electric

2.2.2 Hologic

2.2.3 Siemens Healthcare/Siemens

2.2.4 Others

2.3 Computer-Aided Detection

2.3.1 Carestream Health/Onex

2.3.2 Hologic

2.3.3 iCAD

2.3.4 Scanis

2.4 Emerging Mammography Technology

2.4.1 BBN Technologies

2.4.2 Dexela

2.4.3 GE Healthcare/General Electric

2.4.4 Konica Minolta Medical Imaging/Konica Minolta Holdings

2.4.5 Hologic

2.4.6 Imaging Diagnostic Systems

2.4.7 Philips Healthcare/Royal Philips Electronics

2.4.8 Sectra

2.4.9 Siemens Healthcare/Siemens

2.4.10 XCounter

2.4.11 Others

dtechinsight.com/ReportA409.html. It is a snapshot of the page as it appeared on 5 Dec 2009 22:09:03 GMT. The current page could have changed in the meantime. Learn more

Text-only version
These search terms are highlighted: xcounter These terms only appear in links pointing to this page: ab cancer


Search
The Newsletter
The Principals
Reports
Conferences
Databases
Custom Research
Contact Us
Home
12/16/2009




Online Report Subscribers, Click Here

Pricing and Ordering Information

U.S. Markets for Breast Cancer Detection and Diagnostic Technologies
Report #A409 - October 2009
351 Pages 103 Exhibits - 13 Company Profiles

According to the American Cancer Society (ACS), breast cancer is the most common cancer among women (excluding non-melanoma skin cancers), accounting for more than 1 in 4 cancers diagnosed in United States (U.S.) women. In 2009, approximately 192,370 women will be diagnosed with breast cancer and approximately 40,170 will die of the disease. However, due to the increased awarenesss, availability, and adoption of highly effective breast cancer screening technologies, the average 5-year relative survival rate for early stage, localized breast cancer now approaches 100%, emphasizing the importance of early breast cancer detection and diagnosis.

The U.S. breast cancer detection and diagnostic technologies market (defined in this report as including the 3 core imaging modalities of mammography, magnetic resonance imaging [MRI], and breast ultrasound, as well as minimally invasive breast biopsy and genetic testing) totaled more than $2.1 billion in the U.S. in 2008. This market is expected to grow at a healthy compound annual rate of 5.4% to more than $2.8 billion in 2013, despite the present economic uncertainty, impending healthcare reform, and cost/reimbursement issues.

As the population continues to age and the number of new breast cancer cases increases, the renewed importance on lowering healthcare costs will result in increased utilization of cost-effective, accurate, early cancer detection and prevention technologies. Next-generation imaging technologies that help lower the number of unnecessary biopsies while allowing for earlier detection with increased sensitivity and specificity over conventional mammography will be willingly adopted, and minimally invasive biopsy and genetic testing will continue to flourish. Minimally invasive biopsy systems will be increasingly preferred over open biopsy due to the ability to lessen patient disfigurement and pain. At the same time, the genetic testing products market will benefit from several factors including the ability to assist clinicians in recommending preventive care for women at high risk of contracting breast cancer, while sparing existing breast cancer patients unnecessary painful or ineffective chemotherapy by aiding in the selection of the most appropriate treatment plan.

This dynamic, new report from Medtech Insight includes analyses of products, markets, competitors, and opportunities in the U.S. breast cancer detection and diagnostic technologies market. Product areas include: analog and full-field digital mammography (FFDM) systems; computer-aided detection (CAD); computed radiography detectors; MRI systems and ultrasound systems used in breast imaging; minimally invasive biopsy; BRACAnalysis and other genetic testing (recurrence risk assays); and emerging technologies such as digital tomosynthesis, next-generation breast MRI and ultrasound, and technologies developed by several start-up companies entering the breast cancer detection and diagnostic products field.

Ordering Information

Title
Report# Publication
Date List Price

U.S. Markets for Breast Cancer Detection and Diagnostic Technologies


A409


October 2009


$4,750
Order Online:
Single User only (Please call for corporate subscription pricing) PDF Only

Print versions of Reports are available upon request for an additional fee.

Methodology
Reports are produced exclusively by Medtech Insight, through extensive primary and secondary research among the clinicians, researchers, and competitors in the marketplace, and draw upon the industry expertise of a network of industry insiders. Medtech Insight exhaustively corroborates the data as a baseline for completing forward-looking analysis and providing insight into product, technology and market evolution.



TABLE OF CONTENTS



EXECUTIVE SUMMARY

i. Common Types of Breast Cancer

ii. Symptoms

iii. Risk Factors

iv. Early Detection

v. Treatment

vi. Risk Reduction

vii. Future Directions in Breast Cancer Detection

viii. Breast Cancer Detection and Diagnostic Technologies Market



Exhibit ES-1: Cancer Cases and Deaths, by Anatomic Site, 2007, 2008, and 2009

Exhibit ES-2: 2008, 5-Year Breast Cancer Survival Rates, by Stage

Exhibit ES-3: 2008, Breast Cancer Survival Rates, 5-, 10-, and 15-Years Post-Diagnosis

Exhibit ES-4: Age-Specific Risk of Developing Invasive Breast Cancer

Exhibit ES-5: 2007, Breast Cancer Cases and Deaths, by Age

Exhibit ES-6: Selected Limitations of Mammography

Exhibit ES-7: Selected Breast Cancer Imaging Technologies

Exhibit ES-8: Breast Cancer Detection and Diagnostic Technologies, Combined Market Forecast, 2008-2013

Exhibit ES-9: 2008, Breast Cancer Detection and Diagnostic Technologies Market, Share by Segment

Exhibit ES-10: 2013, Breast Cancer Detection and Diagnostic Technologies Market, Share by Segment

Exhibit ES-11: 2008, Combined Breast Cancer Detection and Diagnostic Technologies Market, Share by Supplier



1. CLINICAL overview

1.1 Common Types of Breast Cancer

1.2 Symptoms

1.3 Risk Factors

1.3.1 Benign Breast Conditions

1.3.2 Family/Personal History

1.3.3 Genetic Risks

1.4 Early Detection

1.5 Treatment

1.5.1 Biologic Therapy, Chemotherapy, and Hormone Therapy

1.6 Risk Reduction

1.7 Future Trends in Breast Cancer Detection



Exhibit 1-1: Cancer Cases and Deaths, by Anatomic Site, 2007, 2008, and 2009

Exhibit 1-2: 2008, 5-Year Breast Cancer Survival Rates, by Stage

Exhibit 1-3: 2008, Breast Cancer Survival Rates, 5-, 10-, and 15-Years Post-Diagnosis

Exhibit 1-4: Age-Specific Risk of Developing Invasive Breast Cancer

Exhibit 1-5: 2007, Breast Cancer Cases and Deaths, by Age

Exhibit 1-6: Benign Breast Disease, by Category

Exhibit 1-7: Selected Benign Breast Diseases

Exhibit 1-8: Selected Limitations of Mammography

Exhibit 1-9: Selected Breast Cancer Imaging Technologies



2. MAMMOGRAPHY

2.1 Analog Mammography Systems

2.1.1 GE Healthcare/General Electric

2.1.2 Hologic

2.1.3 Planmed/Planmeca Group

2.1.4 Siemens Healthcare/Siemens

2.1.5 Others

2.2 Digital Mammography Systems

2.2.1 GE Healthcare/General Electric

2.2.2 Hologic

2.2.3 Siemens Healthcare/Siemens

2.2.4 Others

2.3 Computer-Aided Detection

2.3.1 Carestream Health/Onex

2.3.2 Hologic

2.3.3 iCAD

2.3.4 Scanis

2.4 Emerging Mammography Technology

2.4.1 BBN Technologies

2.4.2 Dexela

2.4.3 GE Healthcare/General Electric

2.4.4 Konica Minolta Medical Imaging/Konica Minolta Holdings

2.4.5 Hologic

2.4.6 Imaging Diagnostic Systems

2.4.7 Philips Healthcare/Royal Philips Electronics

2.4.8 Sectra

2.4.9 Siemens Healthcare/Siemens

2.4.10 XCounter

2.4.11 Others